Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

This study has been completed.
Information provided by (Responsible Party):
Sprout Pharmaceuticals, Inc Identifier:
First received: August 24, 2010
Last updated: May 15, 2014
Last verified: May 2014

This trial examines the way flibanserin is metabolized in postmenopausal women with Hypoactive Sexual Desire Disorder.

Condition Intervention Phase
Sexual Dysfunctions, Psychological
Drug: flibanserin 100 mg dose every evening
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of Single Dose and Steady State Pharmacokinetics of Flibanserin Postmenopausal Women With Hypoactive Sexual Desire Disorder

Further study details as provided by Sprout Pharmaceuticals, Inc:

Primary Outcome Measures:
  • Flibanserin: Area Under the Curve; AUC_0-∞ [ Time Frame: 8 days ] [ Designated as safety issue: No ]
    Geometric mean of the AUC_0-∞ of Flibanserin

  • Flibanserin: AUC τ,ss [ Time Frame: 8 days ] [ Designated as safety issue: No ]
    Geometric mean of the AUC τ,ss of Flibanserin

  • Flibanserin: Cmax (Peak Concentration) [ Time Frame: 8 days ] [ Designated as safety issue: No ]
    Geometric mean of the Cmax of Flibanserin

  • Flibanserin: Cmax,ss [ Time Frame: 8 days ] [ Designated as safety issue: No ]
    Geometric mean of the Cmax,ss of Flibanserin

  • Flibanserin: Tmax,ss [ Time Frame: 8 days ] [ Designated as safety issue: No ]
    Median of the tmax,ss of Flibanserin

Enrollment: 24
Study Start Date: July 2010
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: flibanserin
flibanserin 100 mg dose every evening
Drug: flibanserin 100 mg dose every evening
all subjects receive flibanserin


Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Patients must be in a stable, monogamous heterosexual relationship for at least one year.
  2. Patients must have a primary diagnosis of Hypoactive Sexual Desire Disorder for at least six months.
  3. Patients must be naturally postmenopausal women of any age with at least one ovary.
  4. Patients may participate whether or not they are currently taking systemic hormone therapy provided the therapy was not prescribed for treatment of low sexual desire. Hormone therapy must be at a stable dose for at least six months.

Exclusion criteria:

  1. Patients with a history of drug dependence or abuse within the past twelve months.
  2. Patients who have been previously treated with flibanserin.
  3. Patients who have sexual dysfunctions other than Hypoactive Sexual Desire Disorder, such as: Sexual Aversion Disorder, Substance-Induced Sexual Dysfunction, Dyspareunia, Vaginismus, Gender Identity Disorder,Paraphilia, or Sexual Dysfunction due to a general medical condition.
  4. Patients who indicate that their sexual partner has inadequately treated organic or psychosexual dysfunction that could interfere with a patients response to treatment.
  5. Patients whose sexual function was impaired, in the investigators opinion, by abdominal or vaginal hysterectomy, oophorectomy or any other pelvic, vaginal, or urologic surgery.
  6. Patients with pelvic pain, pelvic inflammatory disease, endometriosis, urinary tract or vaginal infection/vaginitis, cervicitis, interstitial cystitis, vulvodynia, symptomatic vaginal atrophy or any other gynecological pathology requiring further evaluation.
  7. Patients with a history of unexplained vaginal bleeding within the past twelve months.
  8. Patients with a history of Major Depressive Disorder within six months prior to Screening; ; active suicidal ideation with intent in the past ten years or suicidal behavior at any time.
  9. Patients with a history of any other psychiatric disorder that could impact sexual function, increase risks to patient safety, or impair patient compliance. Such disorders include but are not limited to bipolar disorder, psychotic disorders, severe anxiety, eating disorders, and antisocial personality disorders.
  10. Clinically significant electrocardiogram abnormalities at Screening.
  11. Patients with a history of dementia or other neurodegenerative disease; organic brain disease; stroke; transient ischemic attacks; multiple sclerosis; spinal cord injury; brain surgery; significant brain trauma; peripheral neuropathy; and epilepsy.
  12. Patients with ongoing hepatic impairment (cirrhosis, hepatic tumor, or other hepatic disease); peptic ulcer within six months prior to Screening; elevated liver enzymes ; inflammatory bowel disease; gastrointestinal bleeding within two months prior to Screening; Patients who have had bariatric surgery for obesity.
  13. Patients with a history of angina; atherosclerotic cardiovascular disease; congestive heart failure; cardiomyopathy; symptomatic cardiac valve disease; arrhythmia; hypertension.
  14. Patients with a history of renal failure; known history of chronic glomerulonephritis.
  15. Patients with a history of chronic obstructive pulmonary disease, chronic bronchitis, or asthma not well controlled with medication taken twice daily or less.
  16. Patients with a history of gonadotrophic hormone disorders or uncontrolled diabetes mellitus.
  17. Uncorrected hypothyroidism or hyperthyroidism.
  18. Patients with a history of uncontrolled glaucoma.
  19. Patients with known Human Immunodeficiency Virus infection, Acquired Immunodeficiency Syndrome, other clinically significant immunological disorders or auto-immune disorders such as lupus or scleroderma.
  20. Patients with a history of any cancer within the past ten years, other than non-invasive, previously resected basal cell carcinoma of the skin.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01188603

United States, Florida
511.146.01003 Boehringer Ingelheim Investigational Site
Orlando, Florida, United States
United States, Kansas
511.146.01005 Boehringer Ingelheim Investigational Site
Wichita, Kansas, United States
United States, Michigan
511.146.01001 Boehringer Ingelheim Investigational Site
Kalamazoo, Michigan, United States
United States, Tennessee
511.146.01004 Boehringer Ingelheim Investigational Site
Knoxville, Tennessee, United States
Sponsors and Collaborators
Sprout Pharmaceuticals, Inc
Study Chair: Sprout Pharmaceuticals Sprout Pharmaceuticals
  More Information

No publications provided

Responsible Party: Sprout Pharmaceuticals, Inc Identifier: NCT01188603     History of Changes
Other Study ID Numbers: 511.146
Study First Received: August 24, 2010
Results First Received: May 4, 2011
Last Updated: May 15, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Sexual Dysfunctions, Psychological
Mental Disorders
Sexual and Gender Disorders
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Serotonin 5-HT1 Receptor Antagonists
Serotonin 5-HT2 Receptor Antagonists
Serotonin Agents
Serotonin Antagonists processed this record on November 25, 2014